| Basic Medical Informatin |
| brand name |
| Namenda, Namenda Xr |
Zoloft |
| Treatment For |
| Moderate To Severe Dementia Of The Alzheimer's Type |
Depression, Obsessive-compulsive Disorder, Panic Disorder, Anxiety Disorders, Post-traumatic Stress Disorder (ptsd), And Premenstrual Dysphoric Disorder (pmdd) |
| Legal Status |
| Rx-only |
Rx-only |
| Pregnancy cat. |
| B (us) |
C (us) |
| Possible Side Effects |
|
Fever, Sweating, Confusion, Fast Or Uneven Heartbeats, Agitation, Hallucinations, Fever, Overactive Reflexes, Tremors, Nausea, Vomiting, Diarrhea, Loss Of Appetite, Feeling Unsteady, Loss Of Coordination, Or Headache, Trouble Concentrating, Memory Problems, Weakness, Fainting, Seizure, Shallow Breathing |
| Precautions & Contraindications |
| Epilepsy Or Other Seizure Disorder; Cataracts; Liver Disease; Kidney Disease; Bladder Or Kidney Infection |
Hypomania And Seizure Disorders, Liver Or Kidney Damage, Heart Disease, Recent Heart Attack, Bleeding Disorders, Diabetes And Angle-closure Glaucoma |
| Excretion |
| Renal |
Renal |
| Storage Conditions |
| 25°c, In An Airtight Container, Keep Away From Children |
15-30°c |
|
| Dosage, Usage and Forms |
| Forms |
| Tablet |
Tablet |
| Routes (of administration) |
| Oral |
Oral |
|
Dosage |
| 5 mg (5 mg (Namenda), 7 mg (Namenda XR)) |
50 mg |
| Chemical Data |
| Bioavailability |
| 100 % |
44 % |
| Protein binding |
| Hepatic ( |
99 % |
| Metabolism |
|
Hepatic |
| Half Life (hours) |
| 60-100 H |
Approximately 26 H |
| Formula |
| C12h21n |
C17h17cl2n |
| Molecular mass (g/mol) |
| 179.3 G/mol |
306.229 G/mol |